Biokine: BioLineRx – Final Results from Phase 2a Triple Combination Trial of Motixafortide as 2nd Line Therapy in Metastatic Pancreatic Cancer – CBI
Homepage /  Press Release /  Biokine: BioLineRx – Final Results from Phase 2a Triple Combination Trial of Motixafortide as 2nd Line Therapy in Metastatic Pancreatic Cancer

Press Release

Biokine: BioLineRx – Final Results from Phase 2a Triple Combination Trial of Motixafortide as 2nd Line Therapy in Metastatic Pancreatic Cancer